Marshall Wace, LLP Cytosorbents Corp Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.88 - $4.23 $21,965 - $32,262	-7,627 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.05 - $8.11 $39,815 - $79,729	-9,831 Reduced 56.31%	7,627 $31,000
Q2 2021 Aug 13, 2021	BUY	$7.55 - $9.42 $131,807 - $164,454	17,458 New	17,458 $132,000
Q1 2019 May 14, 2019	SELL	$6.82 - $8.56 $27,450 - $34,454	-4,025 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$7.05 - $12.64 $28,376 - $50,876	4,025 New	4,025 $33,000

16.9M

10.1K

500

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $51.9M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.